Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omeros reports record earnings, navigates FDA challenges for growth

Omeros showcased strong financial performance, a robust pipeline, and strategic partnerships in Q4 2022.
While challenges like FDA concerns and tight timelines exist, the company is well-positioned to capitalize on growth opportunities.
With a focus on advancing key programs and maintaining financial stability, Omeros aims to deliver value to shareholders and patients.

Omeros reports Q1 loss, progresses in key programs amid challenges

Omeros' Q1 2023 performance reflected a shift from net income to a significant loss, driven by increased expenses and reduced income, while maintaining a strong cash position and positive sales figures for OMIDRIA.
The company showcased strengths in diversified revenue streams, progress in key clinical programs, and inclusion in the Russell 3000 Index, signaling growth potential and market recognition.
Challenges in regulatory processes, market competition, and resource allocation were evident, requiring strategic navigation and operational efficiency to overcome hurdles and drive future success.
Amidst challenges, Omeros identified opportunities in expanding royalties, advancing clinical programs, exploring new indications, and leveraging immuno-oncology advancements to drive future growth and innovation.

Omeros reports Q2 loss, eyes FDA decisions and revenue growth

Omeros faces challenges with debt maturity and regulatory approvals but benefits from strong revenue streams
The company's pipeline shows promise in addressing various diseases, with a focus on high unmet medical needs
Opportunities lie in expanding revenue through OMIDRIA and advancing key drug candidates towards approval

Omeros reports Q3 losses, highlights pipeline strength and regulatory progress

Omeros demonstrated a mixed financial performance in Q3 2023 but showcased strength in its pipeline and strategic alignment with regulatory authorities.
Challenges persist in financial metrics and regulatory timelines, necessitating a balance between innovation and operational efficiency.
The company's opportunities in immuno-oncology and stable revenue streams position Omeros for future growth and impact in the biopharmaceutical landscape.

Omeros extends cash runway, advances key pipeline candidates for growth

Omeros demonstrated improved financial performance, securing additional funding and advancing key pipeline candidates, positioning the company for future growth.
While facing challenges in regulatory processes and anticipated losses, Omeros' strategic priorities and innovative pipeline offer opportunities for long-term success.
Management's focus on financial stability, operational efficiency, and product differentiation underscores Omeros' commitment to delivering value to shareholders and patients.

Omeros reports increased net loss but optimistic about pipeline progress

Omeros faced a significant increase in net loss in Q1 2024 but maintains a strong financial position with $230.3 million in cash and investments.
The company's development programs, especially OMS906, show promise with positive trial results and potential milestone payments tied to OMIDRIA sales.
While challenges like regulatory approvals and competition exist, Omeros is optimistic about its pipeline and aims for Phase III trials and regulatory successes.
Overall, Omeros is strategically positioned to leverage opportunities for growth and diversification in the biopharmaceutical market.

Omeros reports improved Q3 performance with promising drug developments

Omeros' Q3 2024 performance showed improvements in net loss and strategic financial decisions.
The company's strengths lie in potential revenue streams from OMIDRIA sales and positive trial data.
Challenges include regulatory hurdles and managing costs amidst multiple development programs.
Opportunities exist in sales growth, milestone payments, and advancing key drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022,

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omeros does not have any assets on deposit with Silicon Valley Bank, nor does the company maintain any other financial relationship with the bank or its affiliated entities.

Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023

A $200 million milestone payment sparked a rally in the biopharma's shares this week.

Why Omeros Stock Bolted Higher This Week

Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additional $200M cash, now the enterprise value of the company is around $115M, which we believe is still very cheap for the company's compelling MASP-2 platform.

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

The stock price of Omeros Corporation (NASDAQ: OMER) surged by over 50% intraday today. This is why.

OMER Stock: Over 50% Surge Explained

The Omeros will now be able to fund operations at least through 2025.

Why Omeros Corporation Stock Is Skyrocketing Today

Express

Genetic Technologies

Muscle Maker

SoundHound AI Inc

Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy: 5 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy: 5 To Watch With Big News This Week

SEATTLE--( BUSINESS WIRE )--Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the “Agreement”), pursuant to which Omeros sold its ophthalmology product OMIDRIA® to Rayner in December of 2021.

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

Omeros corporation's hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) should be considered a free option at this point. Narsoplimab has highly compelling phase 2 data on IgAN and a compelling mechanistic rationale.

Omeros: Worst Has Been Priced In, We Like Its IgAN Pipeline, Initiating With A Buy

During its Q3 earnings call, Omeros reported on FDA's initial response to its CRL appeal, setting the stage for progress towards approval. Frustratingly, Omeros has not uttered a peep since its Q3 2022 earnings report.

Omeros' Deafening Silence

Omeros Corporation (NASDAQ:OMER ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Conference Call Participants Colin Bristow - UBS Steve Brozak - WBB Securities Eric Joseph - JPMorgan Mary Kate - Bank of America Brandon Folkes - Cantor Serge Belanger - Needham. Operator Good afternoon and welcome to today's earnings call for Omeros Corporation.

Omeros Corporation (OMER) Q3 2022 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022, which include: For the

Omeros Corporation Reports Third Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company's formal dispute resolution request appealing the issuance by FDA's Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) and the Division of Nonmalignant Hematology (the review division) of a complete response letter (CRL) concerning the biologics license application (BLA) for narsopl

Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes.

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

FDA appeal decision by OND of Narsoplimab for the treatment of patients with HSCT-TMA should be coming in the next few months. Results from the phase 3 ARTEMIS-IGAN study, using Narsoplimab for the treatment of patients with IgA Nephropathy are expected in mid-2023.

Omeros: FDA Appeal On Narsoplimab And Several 2023 Catalysts On Deck

Omeros stock has been drifting with a downward bias since it reported its Q4 2021 earnings. Its problem stems from its protracted delay in getting FDA approval of its narsoplimab in treatment of HSCT-TMA.

Omeros: Taking It To The Max

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, an interest in certain royalty payments based on net sales of OMIDRIA (the “Purchased Receivables”). The royalties payable to DRI comprise a portion of the royalties projected to be paid under the terms of the Asset Purchase Agreement (the “Asset Purchase Agreement”), among Omeros, Rayner Surgical Inc. (“Ra

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)--Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Trial. The analysis in the randomized patient population, including those who declined treatment after randomization, shows that the addition of narsoplimab to treatment of c

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

Omeros' lead therapy, narsoplimab in treatment of High-Risk HSCT-TMA, has fumbled repeatedly in front of the FDA. The FDA's latest chapter in this ongoing saga spells progress with a likely high dose of delay.

Omeros: Off To Never-Never Land

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company's formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros Corporation. (NASDAQ:OMER ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Chief Commercial Officer Conference Call Participants Greg Harrison - Bank of America Steve Brozak - WBB Hannah Adeoye - JPMorgan Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation.

Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2022, which include: For the qua

Omeros Corporation Reports Second Quarter 2022 Financial Results

The consensus price target hints at a 126.2% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Omeros Stock (OMER)